Regeneron Pharmaceuticals, Inc. Stock price

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2023-12-06 pm EST Intraday chart for Regeneron Pharmaceuticals, Inc. 5-day change 1st Jan Change
835.75 USD +1.81% +3.36% +15.84%
Sales 2023 * 12.93B Sales 2024 * 13.51B Capitalization 88.88B
Net income 2023 * 3.82B Net income 2024 * 4.29B EV / Sales 2023 *
6,37x
Net cash position 2023 * 6.46B Net cash position 2024 * 10.66B EV / Sales 2024 *
5,79x
P/E ratio 2023 *
24,6x
P/E ratio 2024 *
22,1x
Employees 12,463
Yield 2023 *
-
Yield 2024 *
-
Free-Float 77.88%
More Fundamentals * Assessed data
Dynamic Chart
Regeneron Pharmaceuticals Insider Sold Shares Worth $5,342,787, According to a Recent SEC Filing MT
TD Cowen Raises Regeneron Pharmaceuticals' Price Target to $1,000 From $900, Keeps Outperform Rating MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-28-2023 08:30 AM CI
Jefferies Adjusts Regeneron Pharmaceuticals Price Target to $937 From $935, Maintains Buy Rating MT
Sector Update: Health Care Stocks Mixed Premarket Monday MT
Regeneron, Sanofi Say Second Phase 3 Trial of Lung Disease Drug Met Its Primary Endpoint MT
Sanofi, Regeneron's Dupixent Lowers Lung Disease Flare-Up in Late-stage Study MT
Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent Investigational Phase 3 Chronic Obstructive Pulmonary Disease Trial CI
Sanofi looks to widen Dupixent use to treat 'smoker's lung' after second trial win RE
Regeneron Pharmaceuticals Insider Sold Shares Worth $5,188,213, According to a Recent SEC Filing MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at 14th Annual Jefferies London Healthcare Conference 2023, Nov-15-2023 02:30 PM CI
Ankyra Therapeutics Announces Clinical Trial Supply Agreement with Regeneron to Evaluate Ank-101 in Combination with Libtayo® in Patients with Cutaneous Squamous Cell Carcinoma CI
Bayer Gets CHMP Backing for Higher-Dose Eylea in Two Major Retinal Eye Diseases DJ
European regulator endorses high-dose version of Bayer eye drug Eylea RE
Transcript : Regeneron Pharmaceuticals, Inc. Presents at UBS Biopharma Conference 2023, Nov-09-2023 11:00 AM CI
More news
1 day+1.81%
1 week+3.36%
Current month+1.45%
1 month+0.40%
3 months+2.12%
6 months+11.71%
Current year+15.84%
More quotes
1 week
802.55
Extreme 802.55
842.00
1 month
783.57
Extreme 783.57
842.00
Current year
668.00
Extreme 668
853.97
1 year
668.00
Extreme 668
853.97
3 years
441.00
Extreme 441
853.97
5 years
271.37
Extreme 271.37
853.97
10 years
257.69
Extreme 257.69
853.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 1988
Chairman 63 1989
Director of Finance/CFO 59 2013
Members of the board TitleAgeSince
Director/Board Member 70 2010
Chief Executive Officer 70 1988
Director/Board Member 81 1991
More insiders
Date Price Change Volume
23-12-06 835.75 +1.81% 554,087
23-12-05 820.9 -0.29% 319,428
23-12-04 823.32 +1.04% 508,434
23-12-01 814.86 -1.09% 560,248
23-11-30 823.81 +1.88% 954,624

Delayed Quote Nasdaq, December 06, 2023 at 04:00 pm EST

More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
835.75USD
Average target price
912.57USD
Spread / Average Target
+9.19%
Consensus
1st Jan change Capi.
+15.84% 88 879 M $
+22.40% 91 081 M $
-5.98% 31 581 M $
+22.25% 27 228 M $
-32.54% 24 090 M $
-24.92% 21 026 M $
-17.26% 18 954 M $
+0.03% 11 738 M $
+22.68% 11 133 M $
-32.57% 8 174 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock Regeneron Pharmaceuticals, Inc. - Nasdaq
As early as today, start finding the best investment opportunities!
Optimize my profits
fermer